about
A comparison of CPAP and CPAPFLEX in the treatment of obstructive sleep apnea in World Trade Center responders: study protocol for a randomized controlled trialTwo-part permutation tests for DNA methylation and microarray dataAnalysis of data with excess zeros.Statistical methods for the analysis of clinical trials data containing many zeros: An application in vaccine development.An Evaluation of Statistical Methods for Analyzing Follow-Up Gaussian Laboratory Data with a Lower Quantification Limit.Analyzing excessive no changes in clinical trials with clustered data.Assessment and Selection of Competing Models for Zero-Inflated Microbiome Data.Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control.Null but not void: considerations for hypothesis testing.Application of two-part statistics for comparison of sequence variant counts.Modeling measurement error in tumor characterization studiesMagnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccineEfficacy outcome selection in the therapeutic hypothermia after pediatric cardiac arrest trialsHigh prescription drug use and associated costs among Medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance networkInterleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases.Multivariate two-part statistics for analysis of correlated mass spectrometry data from multiple biological specimens.Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsA Simple Chi-Square Statistic for Testing Homogeneity of Zero-Inflated Distributions.Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Incorporating founder virus information in vaccine field trials.Accounting for undetected compounds in statistical analyses of mass spectrometry 'omic studies.Managed care's clinical and economic impact on patients with type II diabetes in France: a controlled population-based study.Th17-skewed immune response and cluster of differentiation 40 ligand expression in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis.Two-group comparisons of zero-inflated intensity values: the choice of test statistic matters.A MANOVA test for multivariate lognormal observations with a spike at zero, with application to ecological niches of South Africa.The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected.Patterns of immune response to a vaccine or virus as measured by intracellular cytokine staining in flow cytometry: hypothesis generation and comparison of groups.On statistical tests for homogeneity of two bivariate zero-inflated Poisson populations.Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan.Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.Chop-lump tests for vaccine trials.A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial.Systemic inflammation in dogs with advanced-stage heart failure.Seasonal and annual variation in the food habits of Apennine brown bears, central ItalyPredicting microcystin concentrations in lakes and reservoirs at a continental scale: A new framework for modelling an important health risk factorMarginal and Conditional Approaches to Multivariate Variables Subject to Limit of Detection
P2860
Q23913735-3B1D1B03-F10B-4329-B0CF-F4EDAF082BC5Q24796980-18170D72-F611-47A4-A36C-0EFE092AB0C3Q30716837-D197376D-0C47-4873-B2F2-0084E70EF863Q30824920-C62FC0FD-0C90-47D2-9B64-5DAF141EB36DQ30829516-6730DD78-3868-4797-A861-E34D7FBDE1A9Q30914235-E510D154-3E57-4974-A6C3-D9AD6198647BQ30978870-C9C84950-7898-4FC8-96B1-35A3E727D42BQ33594461-1297BB03-5ED1-4257-A1EF-69232CBFC189Q33666431-F4874287-B2AA-4BC2-A19E-A38840AC88C0Q33918415-0C89DB62-7FF9-4F9D-8480-2EF289D5359EQ33959919-7789BC3E-FC22-4C02-8E40-521F8DA84D2BQ34157802-DA718074-7196-4975-85C6-B2919B5FEED8Q35404461-BFA916DF-70CA-4CCF-B3E6-0736C747ACDCQ35619221-A6C0ECE6-0CE1-4BFE-BEE4-A1C5EFA5E871Q36070332-88D02EAE-C307-4448-BCD0-C980A076681EQ36122695-A3C4B5CB-7BFF-43C2-86A8-45A004B6BE66Q36288468-02D6707E-45BA-4D0F-8B14-BF2DA01F3FBFQ36332432-F25D0722-905C-4A21-B7E4-C7554A3E3C1CQ36487887-F0B51425-454C-4457-A2C7-54F48B778CCAQ36509005-6595406C-AF48-4741-86A9-FC60F86FB2D6Q37528138-7D8BC79F-45B6-466D-9FED-2A687961AA63Q40077696-225D0D06-F46F-4BCA-A65A-DFD6F917F08FQ40367875-1FE31E5C-1DA4-4DE2-9447-B2CD0B816EBCQ41194961-D2F60939-0634-4236-9DF0-F4F23EAF655BQ41679067-CAEC249E-6CC5-4E45-88B2-040A05A5B646Q41782461-82314708-E4E1-42B0-9022-892CCD9EF75CQ45413663-0892085C-D47C-4818-8812-97EC8E3193FAQ45812998-5EA47866-FD40-4ADB-8DE0-381ACAB849B9Q46050727-5AB5B73F-1B5D-4FFC-8BE3-70A5E5157234Q46109094-9C9B46A2-9C8E-4689-9891-8F957BF1C32AQ47894801-36EFF3E5-5487-4E6F-A82F-47E647C7645DQ50475666-A7C1A0B3-019C-4237-BA89-360CA17D6B41Q55073654-B3BD5011-9A95-4AEA-AD3A-F5C12D0CA87BQ56039369-AD72AEAC-CABE-4DB7-B37A-B7EE08994A7DQ58192720-1736EF38-73B5-4A72-B007-2ACDE6AEDEAEQ58322308-1CDFA151-AD10-447E-911E-D1A601175FDA
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Comparisons of two-part models with competitors.
@en
Comparisons of two-part models with competitors.
@nl
type
label
Comparisons of two-part models with competitors.
@en
Comparisons of two-part models with competitors.
@nl
prefLabel
Comparisons of two-part models with competitors.
@en
Comparisons of two-part models with competitors.
@nl
P2860
P356
P1476
Comparisons of two-part models with competitors.
@en
P2093
Lachenbruch PA
P2860
P304
P356
10.1002/SIM.790
P407
P577
2001-04-01T00:00:00Z